Company / Working Capital
AXIM BIOTECHNOLOGIES, INC. Working Capital History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
-$5.8M
FY2023
5-year range
-$5.8M / -$1.3M
FY2019-FY2023
Trend
-77.0%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$1M to -$6M over the past 5 years.
Based on SEC 10-K filings.
-$6M in FY2023.
Declined from -$1M to -$6M over the past 5 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, working capital decreased 77.0% year-over-year.
- Peak working capital was recorded in FY2011.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | -$5.8M | -77.0% |
| FY2022 | -$3.3M | -152.7% |
| FY2018 | -$1.3M | +76.7% |
| FY2017 | -$5.6M | -240.4% |
| FY2016 | -$1.6M | -20.6% |
| FY2015 | -$1.4M | -823.2% |
| FY2013 | -$147.6K | -50.0% |
| FY2012 | -$98.4K | -152.5% |
| FY2011 | -$39.0K | - |
As of FY2023 · SEC 10-K · Updated Jun 29, 2026